Having trouble accessing articles? Reset your cache.

EyeGate's EGP-437 meets Phase III endpoint

EyeGate Pharmaceuticals Inc. (Waltham, Mass.) said transscleral iontophoresis delivery of EGP-437

Read the full 113 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE